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Background/aim: Esmolol and amiodarone are two most commonly used antiarrhythmic drugs in coronary artery bypass grafting
(CABG) surgery. Nevertheless, blockade of beta-2 receptors by increasing doses raise concerns about possible vasospasms. We studied
the vasoactive effects of amiodarone and esmolol on left internal mammary artery (LIMA), radial artery (RA), and saphenous vein (SV)
grafts.
Materials and methods: After determining the presence of functional smooth muscle and endothelial layers, the responses of
submaximally preconstricted graft samples were recorded in a tissue bath system. A total of 96 graft samples from 40 patients were
used: 16 LIMA, 16 RA, and 16 SV grafts for each drug. Esmolol and amiodarone were added to reservoirs separately, starting from a
concentration of 10–8 M until a concentration of 10–4 M.
Results: Although both drugs caused vasodilatation, amiodarone exhibited a more potent vasodilatory effect than esmolol (P < 0.0001
for LIMA, P = 0.0128 for RA, and P < 0.0001 for SV). The vasodilatation rates with esmolol were 48.99 ± 2.28% in LIMA, 49.77 ± 3.03%
in RA, and 41.90 ± 4.05% in SV grafts and with amiodarone they were 71.65 ± 5.18% in LIMA, 58.61 ± 5.87% in RA, and 65.07 ± 4.09%
in SV grafts.
Conclusion: This in vitro study revealed that even increasing doses of both drugs induce vasodilatation of CABG grafts, with amiodarone
having a more potent vasodilatory effect than esmolol.
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1. Introduction
Cardiac arrhythmias are among the most common complications of coronary artery bypass grafting (CABG)
surgery (1). Post-CABG atrial fibrillation (AF) has an
incidence rate of 15% to 50%, while the incidence rate of
nonsustained ventricular tachycardia is 18% to 58% (2,3).
Esmolol and amiodarone are the two most commonly
used drugs in the perioperative period for treatment of
both ventricular and supraventricular arrhythmias. Esmolol is a short-acting parenteral beta-blocker and a Vaughan
Williams class II antiarrhythmic. Amiodarone is a unique
class III antiarrhythmic. Recent studies recommend their
administration preoperatively for prophylaxis of postoperative AF, yielding more frequent utilization (4–6).
The preference of one drug over another, however, is
argumentative. Although amiodarone is an established
peripheral vasodilator, it also possesses noncompetitive
beta-blocker features (6). The vasoactive effects of increas-

ing the doses of amiodarone and esmolol on coronary
conduits are questionable due to reported cases of amiodarone-induced coronary spasm and the fact that increasing
doses of ‘cardioselective’ beta-blockers have vasospastic effects on the peripheral vasculature (7). To the best of our
knowledge, there is no study that assesses whether the use
of these drugs carries the risk of vasospasm and the early
failure of CABG grafts. In this study, we aimed to assess
this risk and compare the in vitro effects of esmolol and
amiodarone on the left internal mammary artery (LIMA),
radial artery (RA), and saphenous vein (SV) grafts in an in
vitro tissue bath system.
2. Materials and methods
Forty consecutive patients (24 male, 16 female)
undergoing CABG for 3-vessel disease were enrolled in
the study after obtaining approval from the local ethics
committee. Patients with diabetes mellitus, peripheral
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arterial disease, chronic renal failure, severe valvular or
ventricular dysfunction defined by an ejection fraction
of <50%, and prior beta-blocker or amiodarone use were
excluded. An equal number of patients were assigned to
each group: 20 patients (12 males and 8 females) for the
esmolol group and 20 patients (12 males and 8 females)
for the amiodarone group. All patients gave informed
consent and took similar medications defined by the
cardiovascular team before the surgery. The vascular
grafts were harvested as described previously (8). The
graft samples were not treated with any pharmacological
agent during or after harvesting. The tissue samples from
the LIMA, RA, and SV grafts obtained during CABG were
placed into 4 °C Krebs solution (with a molar composition
of 122 mmol/L NaCl, 5 mmol/L KCl, 1.25 mmol/L CaCl2,
25 mmol/L NaHCO3, 1.2 mmol/L MgSO4, 1.0 mmol/L
KH2O4, and 11.5 mmol/L glucose) and transported to the
vascular laboratory where they were sliced into vascular
rings 3 mm wide and suspended in a tissue bath system.
Only viable vascular rings with functional endothelium
and smooth muscle layers were used in the study. Out
of 96 viable graft samples, an equal number of grafts was
studied for each drug. More specifically, 16 LIMA, 16 RA,
and 16 SV samples were studied in the esmolol group and
16 LIMA, 16 RA, and 16 SV samples were studied in the
amiodarone group.
2.1. Tissue bath system
The reservoirs in the tissue bath system were filled with
20 mL of 37 °C Krebs solution, which was continuously
oxygenated with a gas mixture composed of 95% O2 and
5% CO2 and changed every 20 min to keep the tissues alive.
The upper ends of the vascular rings were attached to the
force transducer and the lower ends were kept stable. The
viability and contractile function of the vascular smooth
muscle layer were tested through vasoconstrictor response
to 10–6 M phenylephrine, a potent α1 agonist, added to the
bath system. Next, 10–7 M carbachol (Sigma-Aldrich),
a cholinergic agonist, was used to induce endotheliumdependent vasodilatation, which consequently proved the
presence of an intact endothelial layer. After determining
the functionality of the tissue samples, those with both
functional muscular and endothelial layers were washed
thoroughly and kept in Krebs solution without any drug
for 30 min before the experiment.
Before adding the study drug into the bath system,
the grafts were submaximally constricted with 10–6 M
phenylephrine to make any vasodilator or vasoconstrictor
responses to esmolol and amiodarone obvious.
Esmolol (Brevibloc, premixed 250 mL, EczacıbaşıBaxter, İstanbul, Turkey) was added into the reservoir
to achieve a concentration of 10–8 M, and the dose was
incremented half logarithmically in 2-min intervals until
its concentration in the reservoir reached 10–4 M. The

effective plasma concentration of esmolol is 1.56 × 10–4
to 9.93 × 10–4 mg/mL, corresponding to 5.3 × 10–7 M to
3.4 × 10–6 M esmolol composition in the tissue bath. The
responses of the vascular rings to the increased doses of
esmolol were recorded.
Amiodarone (Cordarone, 150 mg IV amp, Sanofi
Aventis, İstanbul, Turkey) was studied in the graft samples
using the same protocol as that used for esmolol. The
concentration of amiodarone in the reservoir was increased
from 10–8 M to 10–4 M half logarithmically in 2-min
intervals. The therapeutic plasma level of amiodarone,
which was defined as 2.5 µg/mL, is equivalent to 3.67 ×
10–6 M tissue bath concentration and was also covered in
the study. The data were transferred to a computer with the
help of the Transducer Acquisition System (MAY IOBS 99,
FDT 05, Ankara, Turkey) and stored using MAY-MASTER
MP36 analysis software. Finally, the concentrationresponse curves were constructed for each drug.
2.2. Statistical analysis
Statistical analyses were performed using IBM SPSS
Statistics 20 for Mac (IBM Corp., Armonk, NY, USA) and
GraphPad Prism Version 4 software (GraphPad Software
Inc., La Jolla, CA, USA). The continuous variables
were presented as mean ± standard deviation (SD) and
categorical variables were represented as percentages.
The continuous variables was compared by independent
samples t-test, and the categorical variables, such as smoking
status, hypertension, and hyperlipidemia, were compared
by chi-square test. The analysis of the data regarding the
vascular responses to the drugs was conducted by oneway ANOVA, and the concentration-response curves were
constructed by GraphPad Prism software. P < 0.05 was
considered to be statistically significant.
3. Results
No significant differences were observed between the
demographic variables of the patients in the esmolol and
amiodarone groups. There were equal numbers of male and
female patients in each group with similar cardiovascular
risk factors (Table 1). The vasodilatation responses to
esmolol and amiodarone were recorded in submaximally
preconstricted graft samples. Table 2 shows the ratio of
vasodilatation responses and log EC50 values of different
graft samples treated with the two drugs. Log EC50, which
is the logarithmic half maximal effective concentration,
represents the potency of the drugs.
When the samples of LIMA, RA, and SV grafts were
analyzed in terms of their response to esmolol treatment,
all of the graft samples exhibited similar amounts of
vasodilatation. The vasodilatation rates with esmolol
were 48.99 ± 2.28% in LIMA, 49.77 ± 3.03% in RA, and
41.90 ± 4.05% in SV grafts. The log EC values of esmolol
in the LIMA, RA, and SV grafts were –5.810, –5.500, and
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Table 1. The demographic characteristics of patients.

Table 2. Vasodilatation responses to esmolol and amiodarone.

Esmolol
group

Amiodarone
group

P-value

Graft
type

Esmolol Vasodilatation Amiodarone
P-value
Log EC
Vasodilatation Log EC

Age
(min–max)

64.5 ± 8.9
(51–82)

64.3 ± 9.5
(46–80)

0.93

LIMA

48.99 ± 2.28

–5.81

71.65 ± 5.18 –5.29

0.0001

Smoking status

3 (15%)

5 (25%)

0.43

RA

49.77 ± 3.03

–5.50

58.61 ± 5.87 –5.09

0.0128

Hypertension

18 (90%)

14 (70%)

0.11

SV

41.90 ± 4.05

–5.44

65.07 ± 4.09 –4.84

0.0001

Hyperlipidemia

16 (80%)

19 (95%)

0.15

Independent samples t-test was used to compare age. Smoking
status, hypertension, and hyperlipidemia were compared by the
chi-square test

–5.440, respectively. There were no statistically significant
differences among the graft types.
The vasodilatation rates with amiodarone were 71.65 ±
5.18% in LIMA, 58.61 ± 5.87% in RA, and 65.07 ± 4.09% in
SV grafts. The log EC values of amiodarone in LIMA, RA,
and SV grafts were –5.290, –5.090, and –4.840, respectively.
Although LIMA graft samples had numerically higher
vasodilatation rates, there were no significant differences
among the graft types. Between the two drugs, on the other
hand, amiodarone exhibited a more potent vasodilatory
effect in all three graft types than esmolol (P < 0.0001 for
LIMA, P = 0.0128 for RA, and P < 0.0001 for SV grafts)
(Figure).
4. Discussion
In this study, we addressed the question of whether
increasing the doses of commonly used drugs, esmolol
(a cardioselective beta-blocker) and amiodarone (a
vasodilator with noncompetitive beta-blocker features),
induces vasospasm in arterial and venous conduits. This
question has two implications:

Figure. Concentration-response curves of esmolol and amiodarone.
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LIMA: Left internal mammary artery, RA: radial artery, SV:
saphenous vein, Log EC: logarithmic half-maximal effective
concentration.

1) Unfavorable vasospastic effect of either drug can
result in fatal graft failure and thus should be avoided.
2) Any favorable effect, such as vasodilatation, may
facilitate the selection between the two drugs in the
treatment of dysrhythmias.
Our study showed that both drugs induce dosedependent vasodilatation of all CABG grafts, including
RA grafts. However, the vasodilatory effect of amiodarone
was significantly higher than that of esmolol, which is of
particular benefit in the perioperative period.
We used esmolol, an ultrashort-acting secondgeneration beta-blocker, as the prototype beta-blocker
for several reasons. As an antiarrhythmic and an
antihypertensive drug, it has an elimination half-life
of 9 min that makes it a favorable choice in immediate
postoperative patients when rapid recovery from
beta-blockage is crucial (9,10). Nevertheless, its use is
not confined to the postoperative period since trials
demonstrated that esmolol reduces myocardial oxygen
consumption, metabolic demands, and thus myocardial
damage when given before cardioplegia or as an additive
to cardioplegia solutions (11). Although it exerts primarily
a beta-1 selectivity at low doses, higher doses carry the
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risk of beta-2 receptor blockade provoking coronary and
vascular spasm. Beta-blockers are shown to attenuate the
expected coronary vasodilatory response to exercise and
enhance the coronary vasoconstrictor response to cold
stress (12,13).
Esmolol also lacks the peripheral vasodilatory features
of the third-generation beta-blockers (14). In our study,
we showed that esmolol had vasodilatory effects on all
CABG grafts. This effect is particularly obvious in arterial
grafts and is of interest for RA grafts, since this conduit is
notorious for its susceptibility to vasospasms. The possible
mechanism of this acute vasodilatory effect is nitric oxide
(NO)-dependent vasodilatation as explained by ArnalichMontiel et al., who demonstrated that esmolol induces
acetylcholine-mediated NO-dependent vasodilatation in
the coronaries of hypertensive rats (15). Similarly, in an in
vivo human study of coronary arteries, esmolol infusion
was shown to increase the minimal luminal diameter
and decrease the endothelial shear stress in patients with
moderate coronary stenosis (16). Our findings support
the literature and reveal that the antiischemic features of
esmolol may go beyond the reduction of heart rate, cardiac
index, or ejection fraction and may be related to coronary
vasodilatation as well.
Amiodarone, a class III antiarrhythmic agent with
sodium, calcium, and potassium channel blocking
properties, is also a noncompetitive alpha- and betablocker (17). In contrast to esmolol, it has a long
elimination half-life of 25 to 50 days and established
coronary and peripheral vasodilatory effects. The exact
mechanism of vasodilatation, however, is not completely
understood. Radhino et al. showed that amiodarone does

not modify smooth muscle contraction in rabbit aorta
strips and proposed that the vasodilatory action is not
through calcium channel blockade (18). Animal studies of
amiodarone have shown that the coronary vasodilatation
induced by amiodarone is highly dependent on NO.
Additionally, amiodarone caused endothelium-dependent
vasodilatation in human vessels both in vivo and in vitro
(19,20). Polysorbate 80, the solvent of the intravenous
amiodarone formulation, is also known to contribute
vasodilatory effects (21).
While both drugs are thought to provoke NOmediated vasodilatation, the significantly higher potency
of amiodarone over esmolol can be attributed to its
additional antioxidative and antiinflammatory features
and to its vasodilatory solvent (22).
Although LIMA grafts are known to possess better
endothelial function and more NO release when compared
to the other grafts, there was no statistically significant
difference among specific graft types with regard to amount
of vasodilatation in the esmolol or amiodarone groups
(23). In other words, LIMA grafts did not perform better
than other grafts. The explanation seems to be related to
the distal and more spastic segment of LIMA that was used
for the purpose of this study.
This in vitro study showed that increasing doses of
both esmolol and amiodarone caused vasodilatation in
all CABG graft samples. Considering the more potent
vasodilatory effect of amiodarone, it may be a more
favorable antiarrhythmic drug than esmolol.
Although in vitro data suggest that both drugs induce
vasodilatation, their safety and efficacy in the perioperative
period should be further addressed in clinical trials.
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